Preclinical Oncology CRO | Contract Research Drug Development Company - CrownBio

Time 2020-09-12 20:04:27

Web Name: Preclinical Oncology CRO | Contract Research Drug Development Company - CrownBio

WebSite: http://www.crownbio.com

ID:44879

Keywords:

CRO,Contract,Preclinical,

Description:

WEBINAR: Next Generation Syngeneic Models to Facilitate Immuno-Oncology ResearchThursday September 24 - 9am/1pm ETJoin Dr Davy Ouyang to discover the latest cutting edge syngeneic research driving immuno-oncology development. Learn more about deep kinetic profiling, and how immune cell depletion studies are used to explore mediation of immunotherapy response. Engineered and bioluminescent syngeneics will also be discussed, as well as novel I/O platforms for moving beyond standard syngeneic studies.NEW PUBLICATION: Barcode Deep NGS-Based Profiling of Oncology Samples Learn how a barcode deep NGS-based method enables highly sensitive characterization of cell lines, xenografts, organoids, and patient samples. Discover how this novel and robust method is used to determine identity, detect contamination, and annotate mouse and human samples. WEBINAR: Animal Model Selection, Study Design, and Current Trends in Preclinical Obesity ResearchWednesday September 30th, 11:00am EDTJoin Dr Fred Beasley to learn more about the key factors to consider when choosing the right rodent model for preclinical obesity studies. Explore how to establish study aims for obesity research, the conventional and next generation obesity models available, and best practice in study design.NEW WHITE PAPER: Learn When and How to Use Tumor Organoids in Oncology Drug Discovery Learn how to select the right in vitro platform for each stage of your drug development program based on model features, benefits, and limitations. Explore the optimal applications of tumor organoids, a superior and predictive research system for oncology drug development, and how to best utilize them alongside conventional platforms.Keeping Your Projects Moving During the COVID-19 PandemicRead the update from Dr. Jean-Pierre Wery, CEO on how we're balancing our operations while keeping our staff and facilities safe. Find out more about our current global capacity - with all China sites fully operational, and a Proxy SD system for EU/US affected areas ON DEMAND WEBINAR: In Silico Applications for In Vitro Drug DiscoveryJoin Dr Sheng Guo to learn how to maximize your oncology in vitro datasets using in silico modeling. Find out how advanced data analysis is used to interrogate cell line and organoid genomics, novel combination regimens, and predictive biomarkers. NEW WHITE PAPER: Discover the Benefits of Biomarker Discovery in Early-Stage Drug DevelopmentExplore three strategies for biomarker discovery and validation early in oncology drug development. Learn how translational preclinical models are used to identify and implement biomarkers across a range of studies, and how to transfer preclinical biomarkers to the clinic for improved accuracy and success rates. ON DEMAND WEBINAR: Tumor Organoids: A Paradigm Shift in Oncology Drug DiscoveryJoin Dr Henry Li, CrownBio CSO and Dr Sylvia Boj, HUB Scientific Director to learn more about HUB tumor organoids and their applications in oncology drug discovery. Find out why organoids better predict patient response, and how they are used to improve cancer drug candidates entering the clinic. WHITE PAPER: Optimizing Translational IBD Capabilities How to Select the Right Preclinical ModelExplore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance. ON DEMAND WEBINAR: Identifying Preclinical Immunotherapy Candidates Using a NHP Exploratory Toxicology PlatformJoin Dr Thomas Scullion to learn how to leverage NHP exploratory toxicology studies to guide and answer multiple immunotherapy developmental questions including lead optimization, dosing paradigms, and immunogenicity endpoints. Discover how NHPs provide a more translational preclinical model for elucidating immune-related toxicity.HuPrime®Patient-Derived Xenografts (PDX)Learn About CrownBio's HuPrime ServiceImmuno-OncologySyngeneic Tumor ModelsLearn About Syngeneic Tumor ModelsCrownBio’s preclinical Translational Technology Platforms provide spontaneous diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.Learn MoreOur unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.Learn MoreModels of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacystudies of antidiabetic agents.Learn More September 24, 2020 WEBINAR: Next Generation Syngeneic Models to Facilitate Immuno-Oncology Research 9am/1pm ET Register Now September 30th, 2020 WEBINAR: Animal Model Selection, Study Design, and Current Trends in Preclinical Obesity Research 11:00am EDT Register Now October 14th, 2020 Virtual Lunch and Learn: Translational Preclinical Platforms for CAR-T Cell Therapy 12-1:00pm BST Register Now

TAGS:CRO Contract Preclinical 

<<< Thank you for your visit >>>

Crown Bioscience is an expert preclinical contract research organization providing oncology services and preclinical cancer models for drug development. CrownBio brings clarity to drug discovery worldwide, helping companies solve today's most pressing problems in immuno-oncology, oncology, cardiovascular, and metabolic diseases.

Hot Websites